Search
forLearn
5 / 801 resultslearn Chestnut Phytocomplex
learn Kopexil
learn Celastrol
learn docosahexaenoic acid
Research
5 / 1000+ results
research OS PLANOS MUNICIPAIS DE SAÚDE COMO FERRAMENTA DE GESTÃO E PLANEJAMENTO: UM LEVANTAMENTO BIBLIOMÉTRICO A RESPEITO DA PRODUÇÃO ACADÊMICA
The document concludes that Passiflora incarnata may help with anxiety, healthcare workers need mental support, common bacteria cause hospital UTIs, telehealth for heart failure needs research, kids' screen time has increased, pregnant teens are mostly okay with their body image, diagnosing post-surgery tuberculosis is hard, older and severely ill people are more likely to have long COVID symptoms, and psychiatrists should be part of pain management teams.
research Cosm-nutraceutical nanovesicles for acne treatment: Physicochemical characterization and exploratory clinical experimentation
Vitamin C-based nanovesicles effectively treat acne.
research Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
research Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review
Caffeine improves hair growth, thickness, and reduces shedding.
research Pharmacokinetic-pharmacodynamic modeling approach for dose prediction of the optimal long-acting injectable formulation of finasteride
Optimal long-acting finasteride injection dose found: 16.8 mg, effective for one month.
Community Join
5 / 115 resultscommunity Cosmo Pharma 2025 Investor Day Report
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Breezula will hit the market in 2026, Cosmo Pharmaceuticals statement!
Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.
community Brief update clascoterone phase 3 - Breezula
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.